GLP1s have added $1T in market cap to Eli and Novo over the last 5 years. That's 3x+ the market cap created by all biopharma startups over the last 30 years combined. This is a bit of an indicment of the biotech startup ecosystem. There are many $1T and even $10T drugs to be invented, we just don't fund them. Through no one persons fault, the... See more

Heard from a seasoned biotech exec: “We have a platform – not just multiple shots on goal.” This is an important distinction. How do teams convince investors that they have a unique platform that could truly spit out dozens of drug candidates? A few thoughts. 1/12

Biotech has a narrative void. Biotech has potential for much much more futuristic and positive outcomes than most other companies. But biotech founders largely miss the opportunity, don’t have priors to narrative building, or see it as a waste of time. If you’re building a company in... See more